JP2013517286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013517286A5 JP2013517286A5 JP2012549107A JP2012549107A JP2013517286A5 JP 2013517286 A5 JP2013517286 A5 JP 2013517286A5 JP 2012549107 A JP2012549107 A JP 2012549107A JP 2012549107 A JP2012549107 A JP 2012549107A JP 2013517286 A5 JP2013517286 A5 JP 2013517286A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- membered
- alkyl
- substituted
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 methylcyclohexyl Chemical group 0.000 claims description 59
- 125000000217 alkyl group Chemical group 0.000 claims description 54
- 125000000623 heterocyclic group Chemical group 0.000 claims description 46
- 150000001875 compounds Chemical class 0.000 claims description 45
- 125000001072 heteroaryl group Chemical group 0.000 claims description 41
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 239000003112 inhibitor Substances 0.000 claims description 28
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims description 8
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 8
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 8
- 239000002777 nucleoside Substances 0.000 claims description 8
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 230000009385 viral infection Effects 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 claims description 4
- 229940123073 Angiotensin antagonist Drugs 0.000 claims description 4
- 101001023866 Arabidopsis thaliana Mannosyl-oligosaccharide glucosidase GCS1 Proteins 0.000 claims description 4
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 claims description 4
- 241000710781 Flaviviridae Species 0.000 claims description 4
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 claims description 4
- 229940124771 HCV-NS3 protease inhibitor Drugs 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 101800001014 Non-structural protein 5A Proteins 0.000 claims description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical class C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000134 cyclophilin inhibitor Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 229960000329 ribavirin Drugs 0.000 claims description 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims description 4
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 3
- 241000711549 Hepacivirus C Species 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims description 2
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims description 2
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims description 2
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 claims description 2
- 241000725619 Dengue virus Species 0.000 claims description 2
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 2
- 241000710912 Kunjin virus Species 0.000 claims description 2
- 241000725177 Omsk hemorrhagic fever virus Species 0.000 claims description 2
- 241000710888 St. Louis encephalitis virus Species 0.000 claims description 2
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims description 2
- 241000710886 West Nile virus Species 0.000 claims description 2
- 241000710772 Yellow fever virus Species 0.000 claims description 2
- 241000907316 Zika virus Species 0.000 claims description 2
- 125000002393 azetidinyl group Chemical group 0.000 claims description 2
- 125000004956 cyclohexylene group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 229940051021 yellow-fever virus Drugs 0.000 claims description 2
- 230000003510 anti-fibrotic effect Effects 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 description 17
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 16
- 125000003342 alkenyl group Chemical group 0.000 description 16
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 12
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 11
- 125000004104 aryloxy group Chemical group 0.000 description 10
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 125000005133 alkynyloxy group Chemical group 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 125000003302 alkenyloxy group Chemical group 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 3
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 description 2
- 0 *C(N(*)c1c(C(O)=O)[s]c(C#C*)c1)=O Chemical compound *C(N(*)c1c(C(O)=O)[s]c(C#C*)c1)=O 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000004419 alkynylene group Chemical group 0.000 description 2
- 125000000732 arylene group Chemical group 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 125000004641 (C1-C12) haloalkyl group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 description 1
- LIEYPKBEPJTWBV-ZECKAXTISA-O CC(C)(C)C#Cc1cc(N([C@H](CC2)CC/C2=[NH+]/OCc2ccccc2)C(C2CCC3(CC3)CC2)=O)c(C(O)=O)[s]1 Chemical compound CC(C)(C)C#Cc1cc(N([C@H](CC2)CC/C2=[NH+]/OCc2ccccc2)C(C2CCC3(CC3)CC2)=O)c(C(O)=O)[s]1 LIEYPKBEPJTWBV-ZECKAXTISA-O 0.000 description 1
- QSBRMGIXSIHKNL-UHFFFAOYSA-N CC(CC1)CCC1C(N(C(C1)=C2SC1C#CC(C)(C)C)N(c1ccccn1)OC2O)=O Chemical compound CC(CC1)CCC1C(N(C(C1)=C2SC1C#CC(C)(C)C)N(c1ccccn1)OC2O)=O QSBRMGIXSIHKNL-UHFFFAOYSA-N 0.000 description 1
- DVYWQKGHPWBWRE-UUNIZHOLSA-N CC(CC1)CCC1C(N([C@H](CC1)CC[C@@H]1NN(C)c1ncccc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound CC(CC1)CCC1C(N([C@H](CC1)CC[C@@H]1NN(C)c1ncccc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O DVYWQKGHPWBWRE-UUNIZHOLSA-N 0.000 description 1
- DVYWQKGHPWBWRE-ULBZPVTCSA-N CC(CC1)CCC1C(N([C@H](CC1)CC[C@H]1NN(C)c1ncccc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound CC(CC1)CCC1C(N([C@H](CC1)CC[C@H]1NN(C)c1ncccc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O DVYWQKGHPWBWRE-ULBZPVTCSA-N 0.000 description 1
- BBUPOXQSCIUXSZ-UHFFFAOYSA-N CC(CC1)CCC1C(N(c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)N(C)C)O Chemical compound CC(CC1)CCC1C(N(c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)N(C)C)O BBUPOXQSCIUXSZ-UHFFFAOYSA-N 0.000 description 1
- CIMPAUUBCFCROW-UHFFFAOYSA-N CC(CC1)CCC1C(N(c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)N(C)CC1CCOCC1)=O Chemical compound CC(CC1)CCC1C(N(c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)N(C)CC1CCOCC1)=O CIMPAUUBCFCROW-UHFFFAOYSA-N 0.000 description 1
- QSQOBEWNOVYBRN-MQZTZHRLSA-N C[C@H](CC1)CC[C@@H]1C(N(C(CC1)CCC1NC(OC(CC1)CCN1C(OC(C)(C)C)=O)=C)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N(C(CC1)CCC1NC(OC(CC1)CCN1C(OC(C)(C)C)=O)=C)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O QSQOBEWNOVYBRN-MQZTZHRLSA-N 0.000 description 1
- 241000282816 Giraffa camelopardalis Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- SEBVTXISLUOJJA-UHFFFAOYSA-N OCC(C1)C11C2(CC2)OCC11CC1 Chemical compound OCC(C1)C11C2(CC2)OCC11CC1 SEBVTXISLUOJJA-UHFFFAOYSA-N 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000005338 substituted cycloalkoxy group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29557610P | 2010-01-15 | 2010-01-15 | |
| US61/295,576 | 2010-01-15 | ||
| PCT/US2011/021279 WO2011088303A1 (en) | 2010-01-15 | 2011-01-14 | Inhibitors of flaviviridae viruses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013517286A JP2013517286A (ja) | 2013-05-16 |
| JP2013517286A5 true JP2013517286A5 (enExample) | 2014-02-20 |
| JP5777223B2 JP5777223B2 (ja) | 2015-09-09 |
Family
ID=43827460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012549107A Active JP5777223B2 (ja) | 2010-01-15 | 2011-01-14 | フラビウイルス科ウイルスのインヒビター |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8524764B2 (enExample) |
| EP (1) | EP2523951B1 (enExample) |
| JP (1) | JP5777223B2 (enExample) |
| KR (1) | KR20120123678A (enExample) |
| CN (1) | CN102712632A (enExample) |
| AP (1) | AP2012006413A0 (enExample) |
| AU (1) | AU2011205797B2 (enExample) |
| BR (1) | BR112012017402A2 (enExample) |
| CA (1) | CA2785563C (enExample) |
| CL (1) | CL2012001959A1 (enExample) |
| CO (1) | CO6561783A2 (enExample) |
| CR (1) | CR20120418A (enExample) |
| EA (1) | EA201290575A1 (enExample) |
| EC (1) | ECSP12012103A (enExample) |
| ES (1) | ES2543105T3 (enExample) |
| MX (1) | MX2012008221A (enExample) |
| NZ (1) | NZ600816A (enExample) |
| PE (1) | PE20121522A1 (enExample) |
| PT (1) | PT2523951E (enExample) |
| SG (1) | SG182478A1 (enExample) |
| UA (1) | UA108221C2 (enExample) |
| WO (1) | WO2011088303A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010276441B2 (en) * | 2009-07-21 | 2015-07-02 | Gilead Sciences, Inc. | Inhibitors of Flaviviridae viruses |
| WO2011031669A1 (en) | 2009-09-09 | 2011-03-17 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
| MX2012008211A (es) * | 2010-01-15 | 2012-08-08 | Gilead Sciences Inc | Inhibidores de virus flaviviridae. |
| US8524764B2 (en) | 2010-01-15 | 2013-09-03 | Gilead Sciences, Inc. | Inhibitors of Flaviviridae viruses |
| PT2734515E (pt) | 2011-07-13 | 2016-03-11 | Gilead Sciences Inc | Derivados de ácido tiofen-2-carboxílico úteis como inibidores de vírus flaviviridae |
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| US8841340B2 (en) | 2012-08-17 | 2014-09-23 | Gilead Sciences, Inc. | Solid forms of an antiviral compound |
| US8759544B2 (en) | 2012-08-17 | 2014-06-24 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
| US8927741B2 (en) | 2012-08-17 | 2015-01-06 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
| MX2017004298A (es) * | 2014-10-01 | 2017-07-19 | Janssen Pharmaceuticals Inc | Indoles mono o disustituidos como inhibidores de la replicacion del virus del denge. |
| US10190162B2 (en) | 2014-10-23 | 2019-01-29 | Complete Genomics, Inc. | Signal confinement sequencing (SCS) and nucleotide analogues for signal confinement sequencing |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| BR112018068676A2 (pt) | 2016-03-31 | 2019-01-15 | Janssen Pharmaceuticals Inc | derivados de indol substituídos como inibidores da replicação viral do dengue |
| BR112018069601A2 (pt) | 2016-03-31 | 2019-01-29 | Janssen Pharmaceuticals Inc | derivados de indolina substituídos como inibidores da replicação viral da dengue |
| BR112018068956A2 (pt) | 2016-04-01 | 2019-01-22 | Janssen Pharmaceuticals Inc | derivados do composto indol substituídos como inibidores da replicação viral da dengue |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| EP3630723B1 (en) | 2017-05-22 | 2022-08-24 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| UA125970C2 (uk) | 2017-05-22 | 2022-07-20 | Янссен Фармасьютікалз, Інк. | Заміщені похідні індоліну як інгібітори реплікації вірусів денге |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| PT3706762T (pt) | 2017-12-07 | 2024-12-05 | Univ Emory | N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos |
| JP2023533016A (ja) | 2020-07-11 | 2023-08-01 | ファイザー・インク | 抗ウイルス性ヘテロアリールケトン誘導体 |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861421A (en) | 1995-12-21 | 1999-01-19 | Smithkline Beecham Corporation | 4,4-(disubstituted) cyclohexan-1-one monomers and related compounds |
| US20050119332A1 (en) * | 1998-03-12 | 2005-06-02 | Lone Jeppesen | Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases) |
| US20020002199A1 (en) * | 1998-03-12 | 2002-01-03 | Lone Jeppesen | Modulators of protein tyrosine phosphatases (ptpases) |
| WO2002100846A1 (en) | 2001-06-11 | 2002-12-19 | Shire Biochem Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
| US6881741B2 (en) * | 2001-06-11 | 2005-04-19 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of Flavivirus infections |
| MXPA05006196A (es) * | 2002-12-10 | 2006-01-27 | Virochem Pharma Inc | Compuestos y metodos para el tratamiento o prevencion de infecciones por flavivirus. |
| KR101058696B1 (ko) * | 2002-12-10 | 2011-08-22 | 바이로켐 파마 인코포레이티드 | 후라비바이러스 감염의 치료 또는 예방을 위한 화합물과방법 |
| DE10359791A1 (de) * | 2003-12-19 | 2005-07-21 | Bayer Healthcare Ag | Substituierte Thiophene |
| WO2005081954A2 (en) * | 2004-02-25 | 2005-09-09 | Wyeth | Inhibitors of protein tyrosine phosphatase 1b |
| WO2005095386A1 (en) | 2004-03-30 | 2005-10-13 | Chiron Corporation | Substituted thiophene derivatives as anti-cancer agents |
| DE102005028077A1 (de) * | 2004-12-22 | 2006-07-13 | Aicuris Gmbh & Co. Kg | Alkinyl-substituierte Thiophene |
| DE102004061746A1 (de) | 2004-12-22 | 2006-07-06 | Bayer Healthcare Ag | Alkinyl-substituierte Thiophene |
| WO2006119646A1 (en) * | 2005-05-13 | 2006-11-16 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
| WO2007093365A2 (en) | 2006-02-15 | 2007-08-23 | Sanofi-Aventis | Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments |
| JP5290186B2 (ja) | 2006-11-15 | 2013-09-18 | ヴァイロケム ファーマ インコーポレイテッド | フラビウイルス感染症の治療または予防用のチオフェン類似体 |
| US20090274655A1 (en) * | 2006-11-17 | 2009-11-05 | Richard Martin Grimes | 2-carboxy thiophene derivatives as anti viral agents |
| CA2750577A1 (en) | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| AU2010276441B2 (en) | 2009-07-21 | 2015-07-02 | Gilead Sciences, Inc. | Inhibitors of Flaviviridae viruses |
| WO2011031669A1 (en) * | 2009-09-09 | 2011-03-17 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
| EP2504329A1 (en) | 2009-11-25 | 2012-10-03 | Vertex Pharmaceuticals Incorporated | 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections |
| MX2012008211A (es) * | 2010-01-15 | 2012-08-08 | Gilead Sciences Inc | Inhibidores de virus flaviviridae. |
| US8524764B2 (en) | 2010-01-15 | 2013-09-03 | Gilead Sciences, Inc. | Inhibitors of Flaviviridae viruses |
| EP2585447A2 (en) * | 2010-06-28 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
| PT2734515E (pt) | 2011-07-13 | 2016-03-11 | Gilead Sciences Inc | Derivados de ácido tiofen-2-carboxílico úteis como inibidores de vírus flaviviridae |
-
2011
- 2011-01-14 US US13/006,761 patent/US8524764B2/en active Active
- 2011-01-14 CA CA2785563A patent/CA2785563C/en active Active
- 2011-01-14 ES ES11701588.3T patent/ES2543105T3/es active Active
- 2011-01-14 SG SG2012051215A patent/SG182478A1/en unknown
- 2011-01-14 KR KR1020127021312A patent/KR20120123678A/ko not_active Withdrawn
- 2011-01-14 MX MX2012008221A patent/MX2012008221A/es active IP Right Grant
- 2011-01-14 PE PE2012001004A patent/PE20121522A1/es not_active Application Discontinuation
- 2011-01-14 UA UAA201208925A patent/UA108221C2/ru unknown
- 2011-01-14 AU AU2011205797A patent/AU2011205797B2/en active Active
- 2011-01-14 EA EA201290575A patent/EA201290575A1/ru unknown
- 2011-01-14 BR BR112012017402A patent/BR112012017402A2/pt not_active IP Right Cessation
- 2011-01-14 EP EP20110701588 patent/EP2523951B1/en active Active
- 2011-01-14 AP AP2012006413A patent/AP2012006413A0/xx unknown
- 2011-01-14 CN CN2011800059739A patent/CN102712632A/zh active Pending
- 2011-01-14 JP JP2012549107A patent/JP5777223B2/ja active Active
- 2011-01-14 WO PCT/US2011/021279 patent/WO2011088303A1/en not_active Ceased
- 2011-01-14 NZ NZ600816A patent/NZ600816A/en not_active IP Right Cessation
- 2011-01-14 PT PT117015883T patent/PT2523951E/pt unknown
-
2012
- 2012-06-29 CO CO12109858A patent/CO6561783A2/es unknown
- 2012-07-13 CL CL2012001959A patent/CL2012001959A1/es unknown
- 2012-08-10 CR CR20120418A patent/CR20120418A/es unknown
- 2012-08-13 EC ECSP12012103 patent/ECSP12012103A/es unknown
-
2013
- 2013-08-02 US US13/958,424 patent/US8884030B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013517286A5 (enExample) | ||
| JP2013517291A5 (enExample) | ||
| JP2012533630A5 (enExample) | ||
| JP5777223B2 (ja) | フラビウイルス科ウイルスのインヒビター | |
| CA2979490C (en) | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor | |
| JP6034883B2 (ja) | ヘテロ三環状部分を有する抗ウイルス性化合物 | |
| JP2014520822A5 (enExample) | ||
| JP2011518835A5 (enExample) | ||
| JP2010539241A5 (enExample) | ||
| RS61064B1 (sr) | Modulatori proteina jezgra hepatitisa b | |
| TW201136942A (en) | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | |
| JP2011521903A5 (enExample) | ||
| JP2012504126A5 (enExample) | ||
| TW201139438A (en) | Analogues for the treatment or prevention of flavivirus infections | |
| WO2015107495A1 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 | |
| US20090060874A1 (en) | Bicyclic pyrrolidine derivatives | |
| KR20080019213A (ko) | 티아졸 화합물 및 그 사용방법 | |
| JP2013514359A5 (enExample) | ||
| EP1444225B1 (en) | Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists. | |
| KR101561964B1 (ko) | 옥사졸리디논 화합물 및 이를 포함하는 c형 간염 예방 또는 치료용 약학 조성물 | |
| JP7154659B2 (ja) | 縮合環含有化合物、その使用及びそれを含む医薬組成物 | |
| JP2015526504A (ja) | Ｈｃｖの大環状プロテアーゼ阻害剤と、非ヌクレオシドｈｃｖ阻害剤と、リトナビルとの組み合わせ | |
| JP2015526504A5 (enExample) | ||
| JP7749545B2 (ja) | Ｔｌｒ７作用薬を含む薬物の組み合わせ | |
| CN114539142A (zh) | 吡啶酮类化合物，其药物组合物、制备方法和应用 |